Connecting Psychiatry - Expert community for all mental health professionals

Major Studies on ECT for Depression: What Have We Learned?

(PSYCHIATRIC TIMES) - These findings were verified in the multisite Consortium for Research in ECT (CORE) collaborative study that used the same populations with the same inclusion and exclusion criteria, evaluations, and time periods as the CUC study.2-8 After remission, the patients were randomly assigned to continuation treatment with the same combination of lithium and nortriptyline or with ECT. The six-month relapse rates for the two treatments were not statistically different from that of the lithium and nortriptyline combination in the CUC study.2

The benefit exhibited with continuation ECT confirms the experience of clinical practice. While medications are easier to administer and are preferred by both patients and practitioners, the efficacy of continuation ECT supports its use in patients who relapse despite the prescription of medications and in those who may not tolerate medications' adverse effects.
Populations and treatments

The studies differed in treatment strategies. In the CORE study, seizures were induced with bitemporal electrode placement (BT) at 50% above a measured seizure threshold (ST). In the CUC study, electrode placement was right unilateral (RUL), with dosages 150% above the ST.

The CUC collaboration enrolled 349 patients and the CORE enrolled 531 patients with severe depression. Clinical characteristics were comparable, with mean ages ranging from 55 to 59 years; 70% were female and the mean pretreatment Hamilton Rating Scale for Depression (HAM-D) scores were 34 (± 7). At treatment end point (remission), HAM-D scores were between 5 and 6 (± 3) in both studies. The episode duration at the time of referral was from 24 to 31 weeks in the CUC study and from 45 to 49 weeks in the CORE study.
ECT efficacy

ECT was effective in both studies. Remission—defined as greater than 60% reduction in HAM-D scores and final scores less than 10—was 87% in CORE and 55% in CUC completers. These rates compared favorably with the 30% remission rate in patients taking citalopram (Celexa), and the 18%, 21%, and 25% reduction rates in patients tak- ing bupropion (Wellbutrin), sertraline (Zoloft), and venlafaxine (Effexor), respectively, in the STAR*D study of patients with nonpsychotic major depression that was diagnosed using DSM-IV criteria.9

The difference in remission rates between the CUC and CORE studies is best ascribed to the technical differences in electrode placement and energy dosing. When the CUC study was designed, RUL electrode placement with energy dosing set at 150% above the calibrated ST was considered effective. These settings were used as the primary treatment in more than 90% of CUC study patients. Recent studies found that stimulating energies must be increased considerably in RUL placements, to at least 500% above the calibrated ST, to match the efficacy of BT electrode placement.10,11 The difference in efficacy is also noted in the number of treatments needed to achieve remission. In the CUC study, the patients received a mean number of 10.2 to 10.8 treatments; of these, 6.6 to 7.7 were RUL treatments. In the CORE study, the mean number of treatments to remission was 7.2 to 7.5—a significant savings in time and cost of an average of three treatments.
Clinical lesson: psychosis

In the data analyses, the populations were stratified by the presence of psychosis.2 Slightly more than one third of the patients were considered to have psychosis as well as depression. In the CORE study, remissions appeared earlier and were more robust—95% of the patients who had psychosis and depression remitted compared with 83% of patients who had nonpsychotic depression (Figure 1).

In the literature on psychotic depression, the efficacy of antidepressants alone is estimated at 30%, antipsychotics alone at 50%, and the combination of two agents at 70%.12 The response to ECT is sufficiently greater than that of medications for clinicians to recommend its use as a primary treatment in preference to repeated trials with medications. Such primary use ensures early relief of mood, thought, vegetative signs, and suicide risk.

For full article, please visit:

Views: 6


You need to be a member of psychiatryRounds to add comments!

Join psychiatryRounds

psychiatryRounds Social Media


CMEinfo: Board Reviews in Anesthesia, Cardiology, Internal Medicine, Radiology

© 2019   Created by PsychiatryRounds Team.   Powered by

Badges  |  Report an Issue  |  Terms of Service